 Arbutus Biopharma Corp NASDAQ: ABUS, X-Chem Inc, and Proteros biostructures GmbH have entered into discovery, research, and license agreement focused on discovering novel inhibitors targeting the SARS-CoV-2 nsp5 main protease Mpro. The collaborations goal is to identify safe and effective therapies against coronaviruses, including SARS-CoV-2. 